St. Jude Children’s Research Hospital shared a post on LinkedIn:
“Joshua Burns, PhD, leads global efforts to better understand how the neuromuscular disorder Charcot-Marie-Tooth disease (CMT) progresses and how it can be measured consistently across studies.
His work has supported the development of standardized outcome measures that are now widely used in clinical trials, improving the ability to evaluate emerging disease-modifying therapies.
CMT is an inherited condition that affects skeletal muscle, sensation and motor function, often beginning in early childhood. Symptoms typically start in the hands and feet and progress over time, leading to balance challenges, muscle weakness and sensory loss that significantly affect daily life.
Over my career, I’ve gone from working as a podiatrist focused on a symptom in the foot to now trying to help treat the whole condition.
– said Burns.
Burns leads the Human Performance, Gait and Mobility Labs at St. Jude, where insights from CMT research are also informing care for patients and survivors with other diseases experiencing treatment-related peripheral neuropathy. This work supports a broader goal of disability prevention through improved assessment, trial design and standards of care.
Learn more about Burns and his CMT research.”
Other articles about St. Jude on OncoDaily.